References
- Zhang J, Chen B, Xu X. Impact on rituximab on incidence of and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: a systemic review and meta-analysis. Leuk Lymphoma 2014;55:509–514.
- Correa D, Shi W, Abrey L, et al. Cognitive functions in primary CNS lymphoma after single or combined modality regimens. Neuro-Oncol 2012;14:101–108.
- NCCN Clinical Practice Guidelines in Oncology. Central Nervous System Cancers. Version 2. National Comprehensive Cancer Network, United States. Inc. 2014. Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
- Caballero MD, Rubio V, Rifon J, et al. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors. Bone Marrow Transpl 1997;20:451–458.
- Wills M, Chopra R, McMillan A, et al. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol 1995;13:588–595.
- Wiebe VJ, Smith BR, DeGregorio MW, et al. Pharmacology of agents used in bone marrow transplant conditioning regimens. Crit Rev Oncol Hematol 1992;13:241–270.
- Abrey LE, Moskowitz CH, Mason WP, et al. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J Clin Oncol 2003;21: 4151–4156.
- Soussain C, Hoang-Xuan K, Taillandier L, et al. Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Societe Francaise de Greffe de Moelle Osseuse-Therapie Cellulaire. J Clin Oncol 2008;26:2512–2518.
- Siegal T, Goldschmidt N. CNS prophylaxis in diffuse large B-cell lymphoma: If, when, how and for whom? Blood Rev 2012;26:97–106.
- Bromberg JE, Doorduijn JK, Illerhaus G, et al. Central nervous system recurrence of systemic lymphoma in the era of stem cell transplantation – an International Primary Central Nervous System Lymphoma Study Group project. Haematologica 2013;98:808–813.
- Subramanyan S, Kennedy MJ. Breast cancer: high-dose therapy. Oncologist 1998;3:289–299.
- Eder S, Labopin M, Finke J, et al. Safety and efficacy of thiotepa-based conditioning therapy for allogeneic transplantation in acute myeloid leukaemia – a survey from the Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation. 56th ASH Annual Meeting and Exposition; 2014 December 6–9, San Francisco, CA. Abstract 3895. Available from: https://ash.confex.com/ash/2014/webprogram/Paper74869.html.
- Eder S, Labopin M, Arcese W, et al. Thiotepa-based vs TBI-based myeloablative conditioning prior to allogeneic stem cell transplantation (HSCT) for acyte myeloid leukaemia (AML) in first complete remission (CR1): a retrospective analysis from the ALWP of the EBMT. Blood 2013;122:2123–2123.
- Oh DH, Chua N, Street L, et al. Treatment of secondary central nervous system lymphoma patients with high-dose Busulfan/Thiotepa-based conditioning and autologous stem cell transplant. Leuk Lymphoma. 2016;57:28–33.
- Cote GM, Hochberg EP, Muzikansky A, et al. Autologous stem cell transplantation with thiotepa, busulfan, and cyclophosphamide (TBC) conditioning in patients with CNS involvement by non-Hodgkin lymphoma. Biol Blood Marrow Transpl 2012;18:76–83.
- Welch MR, Sauter CS, Matasar MJ, et al. Autologous stem cell transplant in recurrent or refractory primary or secondary central nervous system lymphoma using thiotepa, busulfan and cyclophosphamide. Leuk Lymphoma 2015;56:361–367.
- Korfel A, Elter T, Thiel E, et al. Phase II study of central nervous system (CNS)-directed chemotherapy including high-dose chemotherapy with autologous stem cell transplantation for CNS relapse of aggressive lymphomas. Haematologica 2013;98:364–370.